A Study of Peginterferon Alfa-2a in Participants With Chronic Hepatitis B Virus (HBV) in an Expanded Access Program
Status:
Completed
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
This is an expanded access, multicenter, national, open-label, and non-randomized study to
analyze the safety of peginterferon alfa-2a in participants with hepatitis B e antigen
(HBeAg) positive and HBeAg negative chronic HBV infection. All participants will receive 48
weeks treatment of peginterferon alfa-2a monotherapy, followed by a 24 week treatment-free
follow-up period.